Table 1.
Association of AR expression in breast cancer cases with clinicopathological and immunohistochemical features (n=293).a
| Variable | No. of cases (%) | AR expression | P value | ||
|---|---|---|---|---|---|
| Positive n (%) | Negative n (%) | ||||
| 293 (100%) | 180 (61.4%) | 113 (38.6%) | |||
|
| |||||
| Age (years) | <40 | 32 (10.9%) | 21 (65.6%) | 11 (34.4%) | .875 |
| 40–55 | 125 (42.7%) | 76 (60.8%) | 49 (39.2%) | ||
| >55 | 136 (46.4%) | 83 (61.0%) | 53 (39.0%) | ||
| Menopausal status | Pre | 149 (50.9%) | 90 (60.4%) | 59 (39.6%) | .402 |
| Post | 144 (49.1%) | 90 (62.5%) | 54 (37.5%) | ||
| Primary tumor size (T) (n=265, 90.4%) | T1 | 72 (27.2%) | 51 (70.8%) | 21 (29.2%) | .014 |
| T2 | 144 (54.3%) | 87 (60.4%) | 57 (39.6%) | ||
| T3 | 31 (11.7%) | 15 (48.4%) | 16 (51.6%) | ||
| T4 | 18 (6.8%) | 6 (33.3%) | 12 (66.7%) | ||
| Lymph node involvement (n=256, 87.4%) | Negative | 91 (35.5%) | 59 (64.8%) | 32 (35.2%) | .158 |
| Positive | 165 (64.5%) | 95 (57.6%) | 70 (42.4%) | ||
| Metastasis (n=153, 52.2%) | Negative | 129 (84.3%) | 77 (59.7%) | 52 (40.3%) | .150 |
| Positive | 24 (15.7%) | 11 (45.8%) | 13 (54.2%) | ||
| TNM stage group (n=136, 46.4%) | I | 18 (13.2%) | 14 (77.8%) | 4 (22.2%) | .074 |
| II | 56 (41.2%) | 29 (51.8%) | 27 (48.2%) | ||
| III | 38 (27.9%) | 26 (68.4%) | 12 (31.6%) | ||
| IV | 24 (17.7%) | 11 (45.8%) | 13 (54.2%) | ||
| Histological grade (n=285, 97.3%) | Grade 1 | 35 (12.3%) | 23 (65.7%) | 12 (34.3%) | .809 |
| Grade 2 | 153 (53.7%) | 92 (60.1%) | 61 (39.9%) | ||
| Grade 3 | 97 (34.0%) | 58 (59.8%) | 39 (40.2%) | ||
| Lymphovascular invasion (n=282, 69.3%) | Positive | 121 (42.9%) | 71 (58.7%) | 50 (41.3%) | .425 |
| Negative | 161 (57.1%) | 102 (36.4%) | 59 (63.6%) | ||
| ER status (n=283, 96.6%) | Positive | 236 (83.4%) | 154 (65.3%) | 82 (34.7%) | .007 |
| Negative | 47 (16.6%) | 21 (44.7%) | 26 (55.3%) | ||
| PR status (n=273, 93.2%) | Positive | 208 (76.2%) | 131 (63.0%) | 77 (37.0%) | .232 |
| Negative | 65 (23.8%) | 37 (56.9%) | 28 (43.1%) | ||
| HER2/neu status (n=275, 93.9%) | Positive | 62 (22.5%) | 38 (61.3%) | 24 (38.7%) | .968 |
| Equivocal | 13 (4.7%) | 8 (61.5%) | 5 (38.5%) | ||
| Negative | 200 (72.7%) | 126 (63.0%) | 74 (37.0%) | ||
| TNBC (n=281, 95.3%) | Negative | 250 (89%) | 159 (63.6%) | 91 (34.4%) | .075 |
| Positive | 31 (11%) | 15 (48.4%) | 16 (51.6%) | ||
a
Some information was not available for certain criteria and, hence percentages are calculated per cases with available data and missing data were excluded from analysis occurred at random and did not bias the results. Statistical analyses by Pearson’s chi-squared test.